PAREXEL’s Alberto Grignolo Named Fellow by Drug Information Association
June 19 2017 - 7:30AM
Business Wire
Honored for contributing to the advancement of
health care
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced that
Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL
Consulting, has been named a Fellow by the Drug Information
Association (DIA). Dr. Grignolo received the organization’s highest
distinction during the 53rd DIA Annual Meeting in Chicago. The
honorary designation recognizes Dr. Grignolo’s contributions to the
advancement of health care and his leadership within DIA.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170619005031/en/
PAREXEL’s Alberto Grignolo Named Fellow
by Drug Information Association (Photo: Business Wire)
Dr. Grignolo, a 25-year veteran of PAREXEL, is a global expert
on and a frequent contributor to various regulatory, drug
development and management topics. At PAREXEL, he developed the
Company’s Worldwide Regulatory Affairs and Drug Development
Consulting Practices. He also established PAREXEL’s Consulting
Services in Japan during an extended assignment there. Dr. Grignolo
is executive sponsor of a number of global development programs and
advises clients in the areas of drug development strategy,
regulatory negotiation, and best regulatory and clinical
practices.
Additionally, Dr. Grignolo served on the DIA Board of Directors,
has been on the faculty of DIA’s Regulatory Affairs training
courses for more than a decade, and is the Editor of DIA’s member
magazine, Global Forum. In 2015, Dr. Grignolo was awarded the DIA
Inspire Award (Global Connector) for his meritorious service
through leadership roles that have advanced DIA’s mission to foster
innovation and to improve health and well-being worldwide.
“Alberto’s quarter century of leadership at PAREXEL has
furthered our mission of helping clients deliver new therapies to
patients sooner,” said Josef von Rickenbach, Chairman and CEO,
PAREXEL. “This recognition as a DIA Fellow also showcases his
dedication to the advancement of health care. We are proud of his
continued service and commitment to our Company and the many
clients he serves.”
“Alberto personifies DIA. His commitment and passion for health
care product innovation, along with his willingness to share candid
insights from his treasure trove of knowledge, characterize his
many contributions to DIA over the decades. We are thrilled to
count Alberto amongst our leaders and volunteers, and honored to
bestow upon him this well-deserved recognition of Fellow of DIA,”
said Barbara Lopez Kunz, Global Chief Executive, DIA.
About Fellow of DIA Program
Membership into the Fellows of DIA Program is a unique
distinction awarded to long-term, highly engaged members who
continue to contribute to DIA in exemplary ways. This is an
honorary recognition bestowed on less than 1 percent of DIA’s
membership.
Fellows of DIA have demonstrated active support of the
advancement of health care and the health care products arena
through leadership roles for a minimum of 15 years and have proven
engagement in DIA through key volunteer roles in support of major
DIA projects or initiatives.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services company, providing a broad range of
expertise-based clinical research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology, and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619005031/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorKathryn McMahon, PAN CommunicationsTel: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1-781-434-4753Email: ron.aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024